Peter C. Albertsen
University of Connecticut Health Center
EpidemiologyCancerInternal medicineUrologySurgeryOncologyIntensive care medicineProstateAndrogen deprivation therapyDiseaseProstatectomyMEDLINEProstate cancerProstate-specific antigenPopulationGynecologyRadiation therapyFamily medicineMedicineCohort
389Publications
75H-index
20kCitations
Publications 388
Newest
Abstract null null Any effective screening program must satisfy 2 criteria: 1) the test must identify clinically significant disease earlier than its clinical presentation, and 2) a treatment must be available that will alter the natural history of the disease. The controversy surrounding PSA testing that has raged since 1991 centers on these 2 points. Screening and treatment trials published during the past 3 decades have provided critical insights into our understanding of the natural history ...
Source
#1Peter C. Albertsen (University of Connecticut Health Center)H-Index: 75
Serum PSA testing can identify men with clinically significant prostate cancer but exposes many more men to the diagnosis of indolent tumours. Benafif and colleagues have published the results of the BARCODE1 pilot study, in which they propose using germline single-nucleotide polymorphisms to identify men with a genetic risk of developing prostate cancer. Based on their preliminary findings, changing the current prostate cancer screening paradigm will be a challenge.
Source
#1Peter C. Albertsen (University of Connecticut Health Center)H-Index: 75
Source
Source
#1Peter C. Albertsen (University of Connecticut Health Center)H-Index: 75
The prostate-specific antigen (PSA) threshold of 3.0 ng/ml is obsolete because it yields a test that is too sensitive. Urologists should adopt a more nuanced approach that accounts for benign prostate hypertrophy. This includes the use of magnetic resonance imaging, PSA density, and age-specific PSA reference ranges.
Source
#1Vikram LyallH-Index: 1
Last. Benjamin T. RistauH-Index: 13
view all 7 authors...
Source
#1Peter C. Albertsen (University of Connecticut Health Center)H-Index: 75
OBJECTIVE To evaluate the current prostate cancer screening and treatment paradigm in light of recently published long-term results of major screening and treatment trials. METHODS Historical review of the evolution of the diagnosis and treatment of prostate cancer followed by a detailed summary of the findings and differences among the three major screening trials and the three major treatment trials. RESULTS Prostate-specific antigen (PSA) testing can identify clinically significant prostate c...
Source
#1Peter C. Albertsen (University of Connecticut Health Center)H-Index: 75
Source
#1Peter C. Albertsen (UConn: University of Connecticut)H-Index: 75
Source
Reconsidering Prostate Cancer Mortality Since PSA screening and the treatment that may follow result in trading off one cause of death for another, rather than extending life, providers who support...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.